Imrecoxib

Imrecoxib (BAP-909) is a novel and selective cyclooxygenase 2 ( COX-2 ) inhibitor with an IC 50 value of 18 nM, it also inhibits COX1- activity with an IC 50 value of 115 nM. Imrecoxib (BAP-909) has anti-inflammatory effect In Vitro Imrecoxib (BAP-909) (0.1-10 µM; 24 hours) decreases COX-2 mRNA level induced by PMA+LPS at a dose dependent manner in U937 cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. RT-PCRCell Line: U937 cells Concentration: 0.1 µM; 1 µM; 10 µM Incubation Time: 24 hours Result: Decreased COX-2 mRNA level. In Vivo Imrecoxib (BAP-909) (gastrointestinal administration; 5-20 mg/kg; 1 hour before carrageenan injection) inhibits carrageenan-induced acute inflammation, and the inhibitory effect is maximal at 4 hours . Imrecoxib (BAP-909) (gastrointestinal administration; 5-20 mg/kg; started on day 7; 26 days) diminishes the secondary paw swelling and inhibits heat-inactivated BCG induced-inflammtory polyarthritis . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Rat carrageenan-induced edema model Dosage: 5 mg/kg, 10 mg/kg, 20 mg/kg Administration: Gastrointestinal administration; 5-20 mg/kg; 1 hour before carrageenan injection Result: Inhibited the edema response with different doses. Animal Model: Rat adjuvant-induced arthritis (AIA) model Dosage: 5 mg/kg, 10 mg/kg, 20 mg/kg Administration: Gastrointestinal administration; 5-20 mg/kg; started on day 7; 26 days Result: Inhibited adjuvant-induced chronic inflammation at the doses of 10 and 20 mg/kg. Form:Solid IC50& Target:Human COX-1 115 nM (IC 50 ) Human COX-2 18 nM (IC 50 )

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet